Combinations of aldose reductase inhibitors and selective...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/404 (2006.01) A61K 31/18 (2006.01) A61K 31/34 (2006.01) A61K 31/341 (2006.01) A61K 31/405 (2006.01) A61K 31/41 (2006.01) A61K 31/415 (2006.01) A61K 31/4178 (2006.01) A61K 31/4188 (2006.01) A61K 31/42 (2006.01) A61K 31/422 (2006.01) A61K 31/426 (2006.01) A61K 31/427 (2006.01) A61K 31/433 (2006.01) A61K 31/44 (2006.01) A61K 31/4439 (2006.01) A61K 31/454 (2006.01) A61K 31/47 (2006.01) A61K 31/4725 (2006.01) A61K 31/4747 (2006.01) A61K 31/495 (2006.01) A61K 31/517 (2006.01) A61K 31/5377 (2006.01) A61K 4

Patent

CA 2313063

This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor,a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combinations of aldose reductase inhibitors and selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations of aldose reductase inhibitors and selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of aldose reductase inhibitors and selective... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2066842

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.